Author

Natalie Abramov

Observed names: N. Abramov, Nathalie Abramov

Observed institutions: Mayo Clinic, Harvard University, University of Massachusetts Chan Medical School, Massachusetts General Hospital, Teva Pharmaceuticals (Israel)

OpenAlex ID: A5033888688

Markers Distinguishing Mesenchymal Stem Cells from Fibroblasts Are Downregulated with Passaging

2010 · Svetlana Halfon, Natalie Abramov, et al. · Stem Cells and Development · 326

NurOwn, phase 2, randomized, clinical trial in patients with ALS

2019 · James D. Berry, Merit E. Cudkowicz, et al. · Neurology · 163

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

2021 · Haggai Kaspi, Jonathan Semo, et al. · Stem Cell Research & Therapy · 68

Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism

2017 · Nisim Perets, Hadar Segal-Gavish, et al. · Behavioural Brain Research · 54

Repair of Full-Thickness Tendon Injury Using Connective Tissue Progenitors Efficiently Derived from Human Embryonic Stem Cells and Fetal Tissues

2010 · Shahar Cohen, Lucy Leshansky, et al. · Tissue Engineering Part A · 53

Safety of repeated transplantations of neurotrophic factors‐secreting human mesenchymal stromal stem cells

2014 · Yael Gothelf, Natalie Abramov, et al. · Clinical and Translational Medicine · 47

miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors

2017 · Yael Gothelf, Haggai Kaspi, et al. · Stem Cell Research & Therapy · 27

Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes

2024 · Stacy R. Lindborg, Namita A. Goyal, et al. · Muscle & Nerve · 6

Bone Progenitors Produced by Direct Osteogenic Differentiation of the Unprocessed Bone Marrow Demonstrate High Osteogenic Potential In Vitro and In Vivo

2012 · Irene Ginis, Miron Weinreb, et al. · BioResearch open access · 6

In vivo modulation of neurotrophic and inflammatory factors in the CSF of ALS patients treated with NurOwn (MSC NTF cells)

2017 · R. Aricha, M. Cudkowicz, et al. · Cytotherapy · 3

MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells (790)

2020 · Revital Aricha, Natalie Abramov, et al. · Neurology · 1

Beneficial effects of small extracellular vesicles derived from MSC-NTF (NurOwn®) cells on lung inflammation and fibrosis

2026 · Haggai Kaspi, Chen Dekel, et al. · Stem Cell Research & Therapy

Mesenchymal Stem/Stromal Cells: CONSIDERATION OF COMPARTMENT EFFECT ON BIOMARKER ANALYSIS: LESSONS LEARNED FROM BRAINSTORM’S PHASE III CLINICAL TRIAL EVALUATING MSC-NTF CELL THERAPY IN ALS

2023 · N. Blondheim-Shraga, H. Kaspi, et al. · Cytotherapy

Molecular mechanisms underlying MSC-NTF (nurown®) exosome benefits in a mouse LPS-induced ards model

2021 · H. Kaspi, J. Semo, et al. · Cytotherapy

Molecular Characterization of VEGF Secretion by MSC-NTF Cells (NurOwn®): Therapeutic Implications in ALS (P5.2-081)

2019 · Haggai Kaspi, Revital Aricha, et al. · Neurology

NurOwn™: mesenchymal stem cells secreting neurotrophic factors. An autologous cell therapy in clinical trials for ALS

2015 · Yael Gothelf, Yossef Levy, et al. · Cytotherapy

Works count: 16

Citation count: 754

H-index: 7

I10-index: 7